Accelerating Lead Identification by High Throughput Virtual Screening: Prospective Case Studies from the...

Area of Science:

• Drug discovery and medicinal chemistry
• Computational chemistry and cheminformatics
• Structural biology and pharmacology

Background:

• Identifying novel chemical series is crucial for initiating drug discovery programs.
• Challenges in drug discovery include limited structural and ligand data for target proteins.
• Virtual screening methods are essential for efficient hit identification.

Purpose of the Study:

• To demonstrate the impact of high throughput virtual screening (HTVS) in identifying novel chemical series.
• To showcase HTVS utility across three distinct drug targets: Bruton Tyrosine Kinase (BTK), RAR-Related Orphan Receptor γ t (RORγt), and Human Leukocyte Antigen DR isotype (HLA-DR).
• To evaluate HTVS effectiveness in scenarios with varying data availability.

Main Methods:

• Prospective case studies utilizing high throughput virtual screening (HTVS).
• Application of HTVS to BTK, RORγt, and HLA-DR targets with differing data landscapes.
• Analysis of HTVS performance in identifying potent hits.

Main Results:

• HTVS successfully identified novel and diverse chemical series for all three case studies.
• Effective hit identification was achieved despite limited availability of high-resolution structural or ligand binding data.
• The approach proved valuable across projects with varying degrees of data accessibility.

Conclusions:

• High throughput virtual screening (HTVS) is a powerful tool for identifying novel lead series in early-stage drug discovery.
• HTVS demonstrates efficacy even when benchmark data like high-resolution structures are scarce.
• This method accelerates the identification of potent hits for challenging therapeutic targets.